{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T06:08:53Z","timestamp":1778134133394,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100013993","name":"Theravance Biopharma US","doi-asserted-by":"publisher","award":["0"],"award-info":[{"award-number":["0"]}],"id":[{"id":"10.13039\/100013993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10096-019-03683-z","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T15:02:21Z","timestamp":1566658941000},"page":"2323-2330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-2626","authenticated-orcid":false,"given":"Allison R.","family":"McMullen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Lainhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan A.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Shupe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carey-Ann D.","family":"Burnham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,24]]},"reference":[{"key":"3683_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jgar.2018.01.017","volume":"14","author":"Maryam Ghahremani","year":"2018","unstructured":"Ghahremani M, Hosseini Jazani N, Sharifi Y (2018) Emergence of vancomycin intermediate and resistant Staphylococcus aureus among methicillin resistant S. aureus isolated from clinical specimens in the northwest of Iran. J Glob Antimicrob Resist. https:\/\/doi.org\/10.1016\/j.jgar.2018.01.017","journal-title":"Journal of Global Antimicrobial Resistance"},{"key":"3683_CR2","doi-asserted-by":"crossref","unstructured":"Sader HS, Mendes RE, Duncan LR, Pfaller MA, Flamm RK (2018) Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to glycopeptides, daptomycin, and\/or linezolid from U.S. medical centers. Antimicrob Agents Chemother 62","DOI":"10.1128\/AAC.02397-17"},{"key":"3683_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijantimicag.2007.03.015","volume":"30","author":"DJ Biedenbach","year":"2007","unstructured":"Biedenbach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD (2007) Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia\u2013Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY program report (2003\u20132004). Int J Antimicrob Agents 30:143\u2013149","journal-title":"Int J Antimicrob Agents"},{"key":"3683_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1128\/CMR.00042-09","volume":"23","author":"BP Howden","year":"2010","unstructured":"Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML (2010) Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 23:99\u2013139","journal-title":"Clin Microbiol Rev"},{"key":"3683_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.cmi.2017.06.010","volume":"23","author":"M Abbas","year":"2017","unstructured":"Abbas M, Paul M, Huttner A (2017) New and improved? A review of novel antibiotics for Gram-positive bacteria. Clin Microbiol Infect 23:697\u2013703","journal-title":"Clin Microbiol Infect"},{"key":"3683_CR6","first-page":"49","volume":"4","author":"B Das","year":"2017","unstructured":"Das B, Sarkar C, Das D, Gupta A, Kalra A, Sahni S (2017) Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens. Ther Adv Infect Dis 4:49\u201373","journal-title":"Ther Adv Infect Dis"},{"key":"3683_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jgar.2016.07.010","volume":"7","author":"SM Purrello","year":"2016","unstructured":"Purrello SM, Garau J, Giamarellos E, Mazzei T, Pea F, Soriano A, Stefani S (2016) Methicillin-resistant Staphylococcus aureus infections: a review of the currently available treatment options. J Glob Antimicrob Resist 7:178\u2013186","journal-title":"J Glob Antimicrob Resist"},{"issue":"Suppl 2","key":"3683_CR8","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1093\/cid\/civ534","volume":"61","author":"JA Karlowsky","year":"2015","unstructured":"Karlowsky JA, Nichol K, Zhanel GG (2015) Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Clin Infect Dis 61(Suppl 2):S58\u2013S68","journal-title":"Clin Infect Dis"},{"key":"3683_CR9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","volume":"49","author":"DL Higgins","year":"2005","unstructured":"Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP (2005) Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49:1127\u20131134","journal-title":"Antimicrob Agents Chemother"},{"key":"3683_CR10","unstructured":"Theravance Biopharma Antibiotics I. 2016. VIBATIV package insert"},{"key":"3683_CR11","unstructured":"CLSI (2014) Performance standards for antimicrobial susceptibility testing; 24th edition. CLSI document M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute"},{"key":"3683_CR12","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1128\/JCM.02295-09","volume":"48","author":"CA Burnham","year":"2010","unstructured":"Burnham CA, Weber CJ, Dunne WM Jr (2010) Novel screening agar for detection of vancomycin-nonsusceptible Staphylococcus aureus. J Clin Microbiol 48:949\u2013951","journal-title":"J Clin Microbiol"},{"key":"3683_CR13","volume-title":"Performance standards for antimicrobial susceptibility testing: CLSI supplement M100S","author":"CLSI","year":"2016","unstructured":"CLSI (2016) Performance standards for antimicrobial susceptibility testing: CLSI supplement M100S, 26th edn. Clinical and Laboratory Standards Institute, Wayne","edition":"26"},{"key":"3683_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/INF.0b013e3181fe075e","volume":"30","author":"SA Fritz","year":"2011","unstructured":"Fritz SA, Krauss MJ, Epplin EK, Burnham CA, Garbutt J, Dunne WM, Hunstad DA, Storch GA (2011) The natural history of contemporary Staphylococcus aureus nasal colonization in community children. Pediatr Infect Dis J 30:349\u2013351","journal-title":"Pediatr Infect Dis J"},{"key":"3683_CR15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/j.1469-0691.2007.01720.x","volume":"13","author":"K Boye","year":"2007","unstructured":"Boye K, Bartels MD, Andersen IS, Moller JA, Westh H (2007) A new multiplex PCR for easy screening of methicillin-resistant Staphylococcus aureus SCCmec types I-V. Clin Microbiol Infect 13:725\u2013727","journal-title":"Clin Microbiol Infect"},{"key":"3683_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1128\/AAC.01633-12","volume":"57","author":"SA Fritz","year":"2013","unstructured":"Fritz SA, Hogan PG, Camins BC, Ainsworth AJ, Patrick C, Martin MS, Krauss MJ, Rodriguez M, Burnham C-AD (2013) Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections. Antimicrob Agents Chemother 57:559\u2013568","journal-title":"Antimicrob Agents Chemother"},{"key":"3683_CR17","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1128\/JCM.02118-09","volume":"48","author":"JS Hogue","year":"2010","unstructured":"Hogue JS, Buttke P, Braun LE, Fairchok MP (2010) Mupirocin resistance related to increasing mupirocin use in clinical isolates of methicillin-resistant Staphylococcus aureus in a pediatric population. J Clin Microbiol 48:2599\u20132600","journal-title":"J Clin Microbiol"},{"key":"3683_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1128\/JCM.29.3.426-430.1991","volume":"29","author":"WM Johnson","year":"1991","unstructured":"Johnson WM, Tyler SD, Ewan EP, Ashton FE, Pollard DR, Rozee KR (1991) Detection of genes for enterotoxins, exfoliative toxins, and toxic shock syndrome toxin 1 in Staphylococcus aureus by the polymerase chain reaction. J Clin Microbiol 29:426\u2013430","journal-title":"J Clin Microbiol"},{"key":"3683_CR19","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1128\/JCM.01571-14","volume":"52","author":"CL Charlton","year":"2014","unstructured":"Charlton CL, Hindler JA, Turnidge J, Humphries RM (2014) Precision of vancomycin and daptomycin MICs for methicillin-resistant Staphylococcus aureus and effect of subculture and storage. J Clin Microbiol 52:3898\u20133905","journal-title":"J Clin Microbiol"},{"key":"3683_CR20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1128\/JCM.05520-11","volume":"50","author":"B Edwards","year":"2012","unstructured":"Edwards B, Milne K, Lawes T, Cook I, Robb A, Gould IM (2012) Is vancomycin MIC \u201ccreep\u201d method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. J Clin Microbiol 50:318\u2013325","journal-title":"J Clin Microbiol"},{"key":"3683_CR21","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1128\/JCM.01158-12","volume":"50","author":"F Ludwig","year":"2012","unstructured":"Ludwig F, Edwards B, Lawes T, Gould IM (2012) Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 50:3383\u20133387","journal-title":"J Clin Microbiol"},{"key":"3683_CR22","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1128\/JCM.00611-15","volume":"53","author":"RE Mendes","year":"2015","unstructured":"Mendes RE, Farrell DJ, Flamm RK, Sader HS, Jones RN (2015) Analysis of vancomycin susceptibility testing results for presumptive categorization of telavancin. J Clin Microbiol 53:2727\u20132730","journal-title":"J Clin Microbiol"},{"key":"3683_CR23","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1128\/AAC.04052-14","volume":"59","author":"RE Mendes","year":"2015","unstructured":"Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN (2015) Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method. Antimicrob Agents Chemother 59:702\u2013706","journal-title":"Antimicrob Agents Chemother"},{"key":"3683_CR24","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1128\/AAC.04616-14","volume":"59","author":"RE Mendes","year":"2015","unstructured":"Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN (2015) Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States. Antimicrob Agents Chemother 59:1811\u20131814","journal-title":"Antimicrob Agents Chemother"},{"key":"3683_CR25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40121-016-0133-y","volume":"5","author":"JI Smart","year":"2016","unstructured":"Smart JI, Corey GR, Stryjewski ME, Wang W, Barriere SL (2016) Assessment of minimum inhibitory concentrations of telavancin by revised broth microdilution method in phase 3 hospital-acquired pneumonia\/ventilator-associated pneumonia clinical isolates. Infect Dis Ther 5:535\u2013544","journal-title":"Infect Dis Ther"},{"key":"3683_CR26","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.1128\/AAC.00773-15","volume":"59","author":"JR Smith","year":"2015","unstructured":"Smith JR, Barber KE, Hallesy J, Raut A, Rybak MJ (2015) Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic\/pharmacodynamic models. Antimicrob Agents Chemother 59:5529\u20135534","journal-title":"Antimicrob Agents Chemother"},{"key":"3683_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.diagmicrobio.2018.09.003","volume":"93","author":"LD Saravolatz","year":"2019","unstructured":"Saravolatz LD, Pawlak J (2019) VISA-Daptomycin non-susceptible Staphylococcus aureus frequently demonstrate non-susceptibility to telavancin. Diagn Microbiol Infect Dis 93:159\u2013161","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3683_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1086\/589241","volume":"47","author":"R Datta","year":"2008","unstructured":"Datta R, Huang SS (2008) Risk of infection and death due to methicillin-resistant Staphylococcus aureus in long-term carriers. Clin Infect Dis 47:176\u2013181","journal-title":"Clin Infect Dis"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03683-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-019-03683-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-019-03683-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T09:42:19Z","timestamp":1664185339000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-019-03683-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,24]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3683"],"URL":"https:\/\/doi.org\/10.1007\/s10096-019-03683-z","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,24]]},"assertion":[{"value":"14 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (Washington University Human Research Protection Office, IRB ID # 201508039) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Although retrospective studies are conducted on already available data or biological material (for which formal consent may not be needed or is difficult to obtain), ethical approval may be required dependent on the law and the national ethical guidelines of a country. Authors should check with their institution to make sure they are complying with the specific requirements of their country.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval retrospective studies"}}]}}